Replies to post #73729 on Cytodyn Inc (CYDY)

[justdafactss]

Are the ACTIVE lawsuits against Cytodyn's advisor fake too?

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic services provider and an advisor to CytoDyn, will provide a comprehensive update on leronlimab for COVID-19. The Wall Street Reporter's event is scheduled for Friday, May 1, 2020 at 12:30 pm ET / 9:30 am PT.
https://www.marketwatch.com/press-release/cytodyns-drs-pourhassan-and-patterson-to-present-live-at-wall-street-reporters-event-to-discuss-paper-recently-submitted-for-publication-and-positive-results-of-eind-covid-19-patients-2020-04-29

Patterson also mentioned in this 4/30/2020 SEC Cytodyn filing:
https://www.sec.gov/Archives/edgar/data/1175680/000119312520128998/d921147ds3a.htm


http://www.sanmateocourt.org/midx/strip.php?co123=ldovv

[Borel Fields]

How confident are you Patterson's article will appear Tuesday in JAMA? How solid are your sources? This would be huge to know with certainty.

There is a number called the "impact factor" for journals, which tries to measure, well, impact. On that score, the top 3 english-language medical journals are NEJM (70), Lancet (59) and JAMA (51).

Be aware there is one journal simply called "JAMA," and about 15 specialty journals. JAMA Internal Medicine, perhaps? More room for longer articles and discussion. There is an "online first" click-thru on their site.

I was a biostatistician way back in the 1970s - coauthored 8 peer reviewed papers - one was actually in JAMA. Honor, reputation, wow. I think I was one of only two non-MD coauthors in the entire issue.